{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-010417","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.842164+00:00","generated_at":"2026-06-11T18:09:37.036154+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"ENDRA Life Sciences annual meeting elects directors, approves say-on-pay frequency of 1 year","bullets":["All five director nominees elected: Michelon (2,024,988 for), Basenese (1,628,081), DiGiandomenico (1,976,138), Harsh (1,958,901), Tokman (2,054,532).","Say-on-pay approved with 80% of votes cast in favor (1,733,406 for, 340,392 against, 71,792 abstain).","Stockholders recommend say-on-pay every 1 year (1,743,563 votes); board adopts annual frequency until next required vote in 6 years.","RBSM LLP ratified as independent auditor for FY2023 with 94% of votes for (2,794,638 for, 126,032 against, 63,296 abstain)."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-010417","json":"https://secwatch.observer/filing/0001654954-23-010417.json","markdown":"https://secwatch.observer/filing/0001654954-23-010417.md","text":"https://secwatch.observer/filing/0001654954-23-010417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423010417/0001654954-23-010417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423010417/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:09:37.036154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34d23f96bc7d3730e274deaacd6c1dbb50369cd0","claim":"ENDRA Life Sciences Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-08-09 meeting.","evidence_excerpt":"Proposal 3 – The Company’s stockholders recommended, on an advisory basis, holding advisory votes on the compensation paid to the Company’s named executive officers every year: One Year Two Years Three Years Abstain Broker Non-Votes 1,743,563 111,671 241,373 48,983 838,376","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423010417/0001654954-23-010417-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-09"}],"fact_type":"shareholder_vote"},{"claim_id":"3e4b06f7df3b7ba9122b9094afa43f2967e1f318","claim":"ENDRA Life Sciences Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-08-09 meeting.","evidence_excerpt":"Proposal 2 – The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers: For Against Abstain Broker Non-Votes 1,733,406 340,392 71,792 838,376","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423010417/0001654954-23-010417-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-09"}],"fact_type":"shareholder_vote"},{"claim_id":"8e18ddd13c2f24cb4342377e8acd19f3c8d70c39","claim":"ENDRA Life Sciences Inc. shareholders approved Election of five directors to serve until the next annual meeting at the 2023-08-09 meeting.","evidence_excerpt":"The certified results of the matters voted upon at the meeting, which are more fully described in the Proxy Statement for the Annual Meeting as filed with the Securities and Exchange Commission on May 24, 2023 (the “Proxy Statement”), are as follows: Proposal 1 – The Company’s stockholders elected the five directors nominated by the Company’s Board of Directors to serve until the next annual meeting of stockholders and the election of their successors: For Withheld Broker Non-Votes Francois Michelon 2,024,988 120,602 838,376 Louis J. Basenese 1,628,081 517,509 838,376 Anthony DiGiandomenico 1,976,138 169,452 838,376 Michael Harsh 1,958,901 186,689 838,376 Alexander Tokman 2,054,532 91,058 838,376","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423010417/0001654954-23-010417-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-09"}],"fact_type":"shareholder_vote"},{"claim_id":"d923aed669378c4aef41de3b9798a817a7ff5c9a","claim":"ENDRA Life Sciences Inc. shareholders approved Ratification of RBSM LLP as independent registered public accounting firm at the 2023-08-09 meeting.","evidence_excerpt":"Proposal 4 – The Company’s stockholders ratified the appointment of RBSM LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain 2,794,638 126,032 63,296","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423010417/0001654954-23-010417-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}